صورة الغلاف

Determinants of the Availability of Hepatitis C Testing Services in Opioid Treatment Programs: Results From a National Study

محفوظ في:
الحاوية / القاعدة:American Journal of Public Health vol. 104, no. 6 (Jun 2014), p. E75-E82
المؤلف الرئيسي: Frimpong, Jemima A
مؤلفون آخرون: D'Aunno, Thomas, Jiang, Lan
منشور في:
American Public Health Association
الموضوعات:
Financing, Government > statistics & numerical data
Health Care Surveys
Health Services Accessibility > organization & administration
Health Services Accessibility > statistics & numerical data
Hepatitis C > diagnosis
Humans
Opiate Substitution Treatment > statistics & numerical data
Opioid-Related Disorders > complications
Substance Abuse Treatment Centers > organization & administration
Substance Abuse Treatment Centers > statistics & numerical data
United States
United States > US
Substance abuse treatment
Methadone
Drug abuse
Hepatitis
Medical tests
Health care industry
Infections
Validity
Trends
Drug use
Response rates
Disease prevention
Mental health
Health services
Onsite
Narcotics
Mental health care
Public health
Opioids
Treatment programs
Medical treatment
Referrals
Diagnostic tests
Availability
Substance abuse
Prevention programs
Buprenorphine
Blood diseases
Social
الوصول للمادة أونلاين:Citation/Abstract
Full Text
Full Text - PDF
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
مستخلص:We examined trends and organizational-level correlates of the availability of HCV testing in opioid treatment programs. We used generalized ordered logit models to examine associations between organizational characteristics of 383 opioid treatment programs from the 2005 and 2011 National Drug Abuse Treatment System Survey and HCV testing availability. Between 2005 and 2011, the proportion of opioid treatment programs offering HCV testing increased but largely because of increases in off-site referrals rather than on-site testing. HCV testing availability was higher in opioid treatment programs affiliated with a hospital and those receiving federal funds. Opioid treatment programs providing both methadone and buprenorphine were more likely to offer any HCV testing, whereas opioid treatment programs providing only buprenorphine treatment were less likely to offer on-site testing. HCV testing availability was associated with more favorable staff-to-client ratios. The increasing use of off-site referrals for HCV testing in opioid treatment programs likely limits opportunities for case finding, prevention, and treatment. Declines in federal funding for opioid treatment programs may be a key determinant of the availability of HCV testing in opioid treatment programs.   We examined trends and organizational-level correlates of the availability of HCV testing in opioid treatment programs. We used generalized ordered logit models to examine associations between organizational characteristics of 383 opioid treatment programs from the 2005 and 2011 National Drug Abuse Treatment System Survey and HCV testing availability. Between 2005 and 2011, the proportion of opioid treatment programs offering HCV testing increased but largely because of increases in off-site referrals rather than on-site testing. HCV testing availability was higher in opioid treatment programs affiliated with a hospital and those receiving federal funds. Opioid treatment programs providing both methadone and buprenorphine were more likely to offer any HCV testing, whereas opioid treatment programs providing only buprenorphine treatment were less likely to offer on-site testing. HCV testing availability was associated with more favorable staff-to-client ratios. The increasing use of off-site referrals for HCV testing in opioid treatment programs likely limits opportunities for case finding, prevention, and treatment. Declines in federal funding for opioid treatment programs may be a key determinant of the availability of HCV testing in opioid treatment programs.
تدمد:0090-0036
0002-9572
0271-4353
0273-1975
المصدر:ABI/INFORM Global